Clinical Trials Search Results

A Phase 1b/2 Study of AZD0120 (also known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B cell Maturation Antigen in Participants with Relapsed or Refractory AL Amyloidosis

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Participants with Advanced or Metastatic Merkel Cell Carcinoma

An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ Transplant Recipients with Advanced Cutaneous Malignancies

IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma

A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy

Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Keystroke: A Randomized Phase II Study of Pembrolizumab (Keytruda) Plus Stereotactic Re-irradiation versus SBRT Alone For Locoregionally Recurrent or Second Primary Head and Neck Carcinoma

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma